Physician profile
Tyler Nickle
NPI 1972097418
$3,505.39
in general payments reported to CMS, 2019-2025
12 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $902 · 2023: $593 · 2024: $1,763 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Travel and Lodging: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.55 |
| Travel and Lodging | $648.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,949.69 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic, INC. | $1,046.88 | 2023-2024 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $125.35 | 2024-2025 | Sprint Pns System |
| Abbvie INC. | $85.05 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $82.19 | 2022-2024 | Ztlido |
| Pfizer INC. | $63.80 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.14 | 2022-2023 | Relistor |
| Globus Medical, INC. | $33.24 | 2025 | Senza |
| Abbott Laboratories | $22.57 | 2023 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $18.87 | 2022 | |
| Averitas Pharma INC. | $18.04 | 2023 | Qutenza |
| Nalu Medical, INC. | $17.57 | 2024 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Nickle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.